Baseline Assessment

Answer the following questions to assess your knowledge on CSU management.
Thomas B. Casale, MD FAAAAI

Professor of Medicine and Pediatrics
University of South Florida
Morsani College of Medicine
Tampa, FL

Dr Casale is Professor of Medicine at the University of South Florida in Tampa.  He is a Past President of the AAAAI and was Executive Vice President for 10 years. He has served on the board of directors for ATS, WAO, and ABAI and was Chief Medical Advisor of FARE for 4 years. He has worked on bench to bedside research with a special focus on biologics and translational research. He has published over 550 scientific papers and been on editorial boards of multiple journals. He is recognized as one of the world’s top 2% most influential scientists by research.com.

Anil Nanda, MD, FAAAAI, FACAAI, FACP

Asthma and Allergy Center, Lewisville and Flower Mound, Texas
Adjunct Professor of Medicine, Division of Allergy and Immunology,
University of Texas Southwestern Medical Center

Anil Nanda, MD is in solo community-based private practice in Allergy and Immunology in the Dallas-Fort Worth Metroplex area.  He is also Adjunct Professor of Medicine in the Division of Allergy and Immunology at the University of Texas Southwestern Medical Center in Dallas.  He is involved in both local and national allergy organizations, including being the Immediate Past President of the Texas Allergy, Asthma, and Immunology Society.  He is also very involved in the American Academy of Allergy, Asthma, and Immunology (AAAAI), the American College of Allergy, Asthma, and Immunology (ACAAI), and the American Board of Allergy and Immunology (ABAI).

1.
APPLY evidence-based diagnostic guidelines, including appropriate use of laboratory tests and imaging, to optimize the diagnostic workup for patients with CSU
2.
INTEGRATE knowledge of CSU endotypes and validated and emerging biomarkers, including total serum IgE levels, to individualize treatment strategies and predict response to targeted therapies
3.
IMPLEMENT current, evidence-based treatment algorithms for CSU, including appropriate prescribing and dosing of antihistamines, omalizumab, and other therapies, while avoiding inappropriate or unnecessary use of first-generation antihistamines and/or long-term OCS
4.
EVALUATE the efficacy and safety data for novel therapies for CSU to determine the appropriate use and place in therapy for patients with CSU